Analytical methods
Standard exon sequencing combined with western blot analysis are performed as routine tests. 6 
Analytical validation
Sequencing results are confirmed by exon sequencing using different sets of primers. RT-PCR sequencing may be performed to confirm potential splicing mutations. For potential missense mutations, enzyme assays and protein stability may be performed on a research basis using recombinant WRN protein containing the mutations. 6 If genomic rearrangements are suspected, high-density array CGH can be performed.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) The population prevalence of Werner syndrome is unknown. However, it is likely under-diagnosed because of the lack of awareness of this disorder and the relatively non-specific symptoms (absence of pathognomonic signs).
If applicable, prevalence in the ethnic group of investigated person
The prevalence of heterozygous carriers in Japan is approximately 1/167 and it is estimated to be approximately 1/120 in Sardinia. 4,5
Diagnostic setting
Comment: This is an adult-onset disorder. The earliest sign is the lack of a growth spurt during adolescence. Onset of a prematurely aged appearance (gray hair, scleroderma-like skin) typically starts in the 20-30 s followed by the appearance of age-related disorders (cataracts, diabetes mellitus, atherosclerosis, cancers, osteoporosis). 
TEST CHARACTERISTICS

Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: Undetermined. We estimate that it is close to 100%. Index case in that family had not been tested: Undetermined. We estimate that it is 495%. A positive genetic test will alert care providers to the diagnosis of Werner syndrome. Median life span of the patients is 54 years, 3 7 years older than in the report in 1966. 13 Similarly, the median life span of Japanese Werner patients was 53 years. 14 The most frequent causes of deaths are cancers and myocardial
CLINICAL UTILITY
infarction. Management (please describe)
The results of genetic testing can provide a rational basis for regular medical screening for known, common medical conditions seen in Werner syndrome patients, and increase awareness of potential challenges in treatment. There are case reports of special challenges in, for example, the surgical management of leg ulcers and revascularization procedures in patients with Werner syndrome. 15, 16 Although hypersensitivity to genotoxic agents has been demonstrated in cultured cells derived from patients and heterozygotes, the clinical significance for Werner syndrome patients or carriers with regard to modification of chemotherapy protocols for malignancies has not been established. Clinicians should be aware of the possibility of elevated drug sensitivities to genotoxic agents in this patient population. 17 
Will the result of a genetic test influence lifestyle and prevention? If the test result is positive (please describe)
If the result is positive, this confirms the diagnosis of Werner syndrome, and as the manifestations occur over many years, lifestyle changes and preventative measures may be instituted. These include: smoking avoidance, maintaining a healthy weight, treatment of hyperlipidemia if present, and regular exercise to reduce risk of atherosclerosis and type 2 diabetes. Skin care, with avoidance of trauma, and early aggressive treatment of skin ulcers helps to reduce morbidity from this complication. Annual ophthalmologic exam for cataracts, lipid profile, diabetes and hypertension screening are recommended if the diagnosis is confirmed.
If the test result is negative (please describe) If the test result is negative, this reduces the likelihood of Werner syndrome, and then, atypical Werner syndrome caused by LMNA mutations and other causes should be considered. Symptomatic treatment of clinically significant conditions (diabetes, hyperlipidemia, cataracts) is still indicated.
Which options in view of lifestyle and prevention does a person at risk have if no genetic test has been done (please describe)?
No special options; prevention is not possible.
3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.10 'C' was marked)
Does the result of a genetic test resolve the genetic situation in that family?
If the test is positive and diagnostic, then the unaffected sibs have a 2/3 chance to be a carrier. As in other rare autosomal recessive diseases, they could be tested to determine their carrier status and their partners could be tested to obtain a more accurate recurrence risk. The parents of an index patient with Werner syndrome are obligate carriers, and their sibs or other relatives may also wish to undergo genetic testing to determine their carrier status. Children of a person affected by Werner syndrome are obligate carriers; their partners could be offered genetic testing to obtain a more accurate recurrence risk. 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)
Although there is no cure for Werner syndrome, the diagnosis helps to guide appropriate medical management and screening for diseases common in persons with Werner syndrome (regular exams for cataracts, screening for diabetes, atherosclerosis). Treatment in general is similar to the general population. Although elevated sensitivity to genotoxic drugs has been demonstrated in vitro in cells derived from WS patients, and heterozygotes, the clinical significance has not yet been determined. Clinicians should be aware of the potential for increased sensitivity to genotoxic drugs. 17 An affected person could learn that his or her children are unlikely to be affected by Werner syndrome.
